This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): ABT-165
Description: ABT-165 is a dual-variable domain immunoglobulin that targets VEGF and DLL4. DLL4 is a notch pathway ligand involved in angiogenesis and maintenance of tumor stem cells. The dual activity of ABT-165 is designed to address the emerging clinical challenge of tumor resistance to anti-VEGF therapies.
Additional information available to subscribers only: